Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Cellectis S.A.NASDAQ: CLLS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$17.83M, compared with -$18.13M a year earlier. Trailing-twelve-month net income was -$67.29M.

Context

  • Net income amounted to 92.7% of revenue in FY2025, up 4.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$121.46M (-79.7%) for the fiscal year ending Dec 2026, a step up from the -83.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.83M+32.3% QoQ
Last fiscal yearDec 2025
-$67.59M-83.9% YoY
LTMMar 2026
-$67.29M-11.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%-11.6%-13.2 pp
1 year-83.9%-79.7%+4.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(67.59M) USD
Year-over-year change
-83.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.2% is the 4th highest of 10, against a peer median of -27.1%.
  • Net income amounts to 98.8% of revenue for CLLS, versus a peer median of 2954.1%.
CLLS Competitors
Net Income for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
AMRNAmarin Corporation plcLTM Mar 2026-$33.61M USD+61.8%—15.6%
MREOMereo BioPharma Group plcLTM Mar 2026-$35.7M USD+24.2%—7139.7%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$56.88M USD-75.2%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.1%—1788.8%
CLLSCellectis S.A.LTM Mar 2026-$67.29M USD-11.2%—98.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$74.31M USD-17.6%——
SLNSilence Therapeutics plcLTM Mar 2026-$85.17M USD——9243.0%
KRROKorro Bio, Inc.LTM Mar 2026-$113.5M USD-29.8%—2954.1%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$166.01M USD-74.3%——
DBVTDBV Technologies S.A.LTM Mar 2026-$167.85M USD-47.7%——
Peer median (excluding CLLS) —-27.1%—2954.1%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.